Expansion of Targeted Sequencing Panels in Genetic Disease and Pathogen Detection and Key Compliance Points

Multi-scenario applications: from oncology to genetic diseases and pathogen detection

The concept of targeted sequencing panels is not limited to oncology. For genetic disease diagnosis, panels can cover genes associated with a specific disease or disease group to assist in determining pathogenic variants; in pharmacogenomics, panels can be used to detect common loci related to drug metabolism and transport, providing a reference for personalized medication; in the field of infectious diseases, targeted sequencing panels can enrich nucleic acids of specific pathogens to assist in pathogen identification and drug-resistance gene analysis. In different scenarios, there are significant differences in gene selection, detection scope, and performance requirements for panels.

Genetic disease panels usually need to cover exons and splice regions, and some also need to include known pathogenic variants in non-coding regions; pharmacogenomics panels often focus on clearly defined star alleles or haplotypes; pathogen-targeted panels need to balance the coverage of variant strains by probe design. Users should avoid simply applying the performance metrics of oncology panels and should reevaluate based on the specific application.

Matching performance verification with intended use

Whether they are commercial kits or laboratory-developed methods, targeted sequencing panels should have performance verification appropriate to their intended use before formal use. Performance verification items generally include accuracy, repeatability, analytical sensitivity, specificity, interference resistance, and stability. For genetic disease testing, attention should also be paid to the interpretation rules for inheritance patterns and the classification of variant pathogenicity; for pathogen detection, the coverage of different types, subtypes, or mutant strains should be evaluated, and attention should be paid to whether internal controls and contamination prevention measures are included.

The description of intended use should be clear and restrained. For example, statements such as use for auxiliary diagnosis, providing medication reference, or research analysis need to be consistent with the actual verification scope of the product. Claims of efficacy beyond the verification scope or therapeutic implications should not appear in promotional materials, and absolute or guaranteed language should be avoided.

Medical device compliance and laboratory quality management

In mainland China, targeted sequencing panels used for clinical diagnosis may fall within the scope of medical device regulation, depending on their intended use and product form. Commercial kits generally need to obtain the corresponding medical device registration certificate or filing certificate; internal testing methods established and used by medical institutions themselves and not circulated as commercial products should be run under the framework of laboratory-developed tests that comply with relevant quality management requirements. Units purchasing and using them should check product labels, instructions, registration or filing information, applicable sample types, and intended use.

Confirm whether the product has registration or filing certificates corresponding to its clinical use;

Check the sample type, nucleic acid input amount, storage conditions, and shelf life in the instructions;

Check whether the product provides a list of covered regions and a summary of performance verification;

Establish department-level systems for performance validation, personnel training, and adverse event recording.

Compliant use of targeted sequencing panels is not only a regulatory requirement but also the basis for ensuring traceability of results and patient safety. Laboratories should also pay attention to external quality assessment, internal quality control, and calibration and maintenance of instruments and equipment to continuously improve testing quality.

Promotional boundaries in selection and promotion

In external introductions or training materials, content involving targeted sequencing panels should objectively describe the detection scope and performance, and avoid statements such as solving all problems at once. It may explain the number of genes covered by the panel, methodological principles, applicable samples, and report content, but should not promise specific clinical outcomes. As the industry becomes more standardized, instructions, promotional pages, and academic promotion for testing products and services should remain cautious, emphasizing qualifiers such as auxiliary, reference, and preliminary judgment.

Overall, targeted sequencing panels have practical value in multiple scenarios, but only under the premise of compliance, sufficient verification, and professional interpretation can they better serve clinical and research needs.